PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15914125-10	2005	Significantly, rapamycin completely inhibited the phosphorylation of p70(S6K), an mTOR-regulated kinase implicated in the control of proliferation, but had no effect on collagen or total protein synthesis.	Sirolimus	15-24	annexin A6	Homo sapiens	69-72	
12692902-6	2003	As well, rapamycin, a p70 S6 kinase inhibitor, blocked the ATP-mediated proliferative response in NSCs.	Sirolimus	9-18	annexin A6	Homo sapiens	22-25	
9878560-4	1998	Similar to p70(S6K), p70(S6Kbeta) was activated by serum stimulation, and the serum-induced activation was inhibited by wortmannin and rapamycin.	Sirolimus	135-144	annexin A6	Homo sapiens	11-14	
11777993-7	2002	Addition of the macrolide, rapamycin, to fibroblast culture medium blocked the up-regulation by GD-IgG of IL-16, implicating the FRAP/mTOR/p70(s6k) pathway in the induction of IL-16 expression.	Sirolimus	27-36	annexin A6	Homo sapiens	139-142	
10551813-4	1999	Further characterization of ROS-induced activation of p70(S6k) using specific inhibitors for p70(S6k) signaling pathway, rapamycin, and wortmannin revealed that ROS acted upstream of the rapamycin-sensitive component FRAP/RAFT and wortmannin-sensitive component phosphatidylinositol 3-kinase, because both inhibitors caused the inhibition of ROS-induced p70(S6k) activity.	Sirolimus	121-130	annexin A6	Homo sapiens	54-57	
9873056-3	1999	Amino acid-induced p70(s6k) activation was completely inhibited by rapamycin but only partially inhibited by wortmannin.	Sirolimus	67-76	annexin A6	Homo sapiens	19-22	
11872747-9	2002	Prevention of IL-6-induced p70 activation and 4E-BP1 phosphorylation by the mammalian target of rapamycin inhibitors rapamycin and CCI-779 resulted in inhibition of IL-6-induced myeloma cell growth.	Sirolimus	96-105	annexin A6	Homo sapiens	27-30	
10753954-7	2000	Rapamycin blocked p70(S6k) phosphorylation induced by NO and also inhibited p53 phosphorylation and p21 expression whereas PD98059 only prevented the NO-induced increase in p21 protein without influencing either p53 activation or p21 mRNA expression.	Sirolimus	0-9	annexin A6	Homo sapiens	18-21	
8939971-3	1996	The effects of insulin were attenuated by rapamycin and wortmannin, two agents that block activation of p70(S6K).	Sirolimus	42-51	annexin A6	Homo sapiens	104-107	
9249059-4	1997	Since ribosomal protein S6 was rapidly dephosphorylated following wortmannin and rapamycin treatment, and the phosphorylation status of the eukaryotic initiation factor 4E was unchanged, our data imply that the p70 signalling pathway has at least one branch-point upstream of FRAP leading to an additional route of translational control.	Sirolimus	81-90	annexin A6	Homo sapiens	211-214	
26006020-9	2015	Fibrin-cultured cells treated with rapamycin, the mTOR pathway inhibitor, had significantly decreased phospho-p70(s6k) and PDX-1 expression.	Sirolimus	35-44	annexin A6	Homo sapiens	110-113	
8663315-5	1996	Treatment with wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase), or with rapamycin, an inhibitor of the pathway from the insulin receptor to p70/p85 ribosomal S6 protein kinase (p70(s6k)), prevented the induction of HKII mRNA by insulin.	Sirolimus	96-105	annexin A6	Homo sapiens	164-167	
8663315-5	1996	Treatment with wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI 3-kinase), or with rapamycin, an inhibitor of the pathway from the insulin receptor to p70/p85 ribosomal S6 protein kinase (p70(s6k)), prevented the induction of HKII mRNA by insulin.	Sirolimus	96-105	annexin A6	Homo sapiens	201-204	
22132975-2	2011	Deoxyribose (dR; a downstream TPase-product) addition to endothelial cells may stimulate FAK and p70/S6k signaling, which can be inhibited by rapamycin.	Sirolimus	142-151	annexin A6	Homo sapiens	97-100	
22785114-5	2012	Rapamycin efficacy was monitored measuring p70 phosphorylation in peripheral blood mononuclear cells.	Sirolimus	0-9	annexin A6	Homo sapiens	43-46	
22785114-6	2012	RESULTS: Both rapamycin doses significantly reduced p70 phosphorylation.	Sirolimus	14-23	annexin A6	Homo sapiens	52-55	
18156399-11	2008	Jejunal villi of the Rapa-treated group showed inactivation of p70(S6k) and a decrease in mucosal resistance (reflecting increased permeability), the latter of which was reversed by Arg.	Sirolimus	21-25	annexin A6	Homo sapiens	63-66	
21525000-4	2011	Short rapamycin treatment specifically inhibiting mTORC1 suppressed p70 but not p85 phosphorylation, suggesting that p85 might be directly activated by phosphatidic acid.	Sirolimus	6-15	annexin A6	Homo sapiens	68-71	
16952420-3	2007	Therefore, the effects of insulin and rapamycin (an inhibitor of mTOR) on the phosphorylation of mTOR (Ser 2448) and p70(S6K) (Thr 389) as well as on cell proliferation in parental HepG2 cells and HepG2 cells overexpressing constitutively active Akt/PKB (HepG2-CA-Akt/PKB) were studied.	Sirolimus	38-47	annexin A6	Homo sapiens	117-120	
16870609-3	2006	mTORC1 (mTOR complex 1) is rapamycin-sensitive and regulates the rate of protein synthesis in part by phosphorylating two well established effectors, S6K1 (p70 ribosomal S6 kinase 1) and 4E-BP1 (eukaryotic initiation factor 4E-binding protein 1).	Sirolimus	27-36	annexin A6	Homo sapiens	156-159